CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an  audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:

• Clinical role of Ki-67 testing
• Core biopsies for identifying potential benefit with neoadjuvant endocrine therapy
• Combining CDK4/6 inhibition with tamoxifen

Presenters:

Javier Cortes, MD, PhD
Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Stephen R. D. Johnston, MA, FRCP, PhD
Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Sara Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F Smith Center for Women’s Cancer
Director of Clinical Trials, Breast Oncology  
Director of Breast Immunotherapy  
Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including downloadable slides and associated Podcast Pearls PDF:
https://bit.ly/37tfvtj

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.